Discovery of new tumor suppressor for lung cancer
Drug-eluting stents reduced the risk of revascularization, heart attack and death in diabetics as compared with bare-metal stents in the largest observational comparison, researchers reported at the American Heart Association’s Scientific Sessions 2008. The results from The Drug-eluting and Bare Metal Stenting in Patients with Diabetes Mellitus: Results from the Mass-DAC Registry, were presented
Full Post: Drug-eluting better than bare metal stents in diabetics
Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help scientists develop more targeted drug therapies to combat lung cancer.
The study, led by Jorge Moscat, PhD, appears in the January 2009 issue of Molecular and Cellular Biology .
Proto-oncogenes are genes that play a role in normal cell growth (turnover of cells and tissue) but, when genetically modified, can cause the out-of-control cell division that leads to cancer. Previous research had established that Ras, a proto-oncogene, is abnormally expressed in up to 25 percent of human lung cancers; however, researchers did not understand the specific cellular events by which abnormal Ras expression leads to transformation.
UC researchers sought to define the interim steps that occur in Ras-induced tumor development to better understand the underlying biological mechanisms leading to cancer.
“These interim steps are critical because they help us determine how best to intervene and stop cancer growth along the way,” explains Moscat, corresponding author of the study and chair of UC’s cancer and cell biology department. “Right now, cancer therapy is delivered with a sledgehammer and it needs to be more like a scalpel so we avoid unnecessary harm to the body.”
Using a genetically modified mouse model, the UC team found that animals who didn’t express a certain gene (protein kinase C (PKC)-zeta) developed more Ras-induced lung cancer, suggesting a new role for the gene as a tumor suppressor.
“PKC-zeta would normally slow down Ras transformation and put the brakes on tumor development, but when PKC-zeta is missing or inactive as a result of genetic alterations, tumor growth actually accelerates,” explains Moscat. “Until now, we did not know the specific chain of events that led to Ras-induced lung cancer. Our study fills in important missing information that will enhance our overall understanding of how lung cancer tumors grow and spread.”
When researchers look inside human cancer cells for the whereabouts of an important tumor-suppressor, they often catch the protein playing hooky, lolling around in cellular broth instead of muscling its way out to the cells’ membranes and foiling cancer growth. This phenomenon of delinquency puzzled scientists for a long time - until a cell biologist
Full Post: Scientists genetically grab PTEN by the tail to curtail cancer
A study led by researchers at The University of Nottingham has identified a gene that protects the body from lung cancer. The research, published in the journal Proceedings of the National Academy of Sciences, USA and funded by a £72,000 grant from the British Lung Foundation, has found that the tumour suppressor gene, LIMD1, is
Full Post: Discovery of gene that protects against lung cancer
A possible new therapeutic target for pancreatic cancer, the most lethal form of human cancer, has been identified in the proteins whose DNA recipe comes from gene, “Seven-In-Absentia,” according to researchers at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco. In their studies with the fruit fly,
Full Post: Possible new therapeutic target for pancreatic cancer
Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers. The discovery could one day lead to an effective gene therapy for cancer. According to Paul B. Fisher, M.Ph., Ph.D., professor and chair of
Full Post: New anti-tumor gene called SARI
Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children. The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is
Full Post: Study links MiR-29 molecule to muscle maturation, muscle cancer